Vaxart Appoints New CMO, Director; Discloses Officer Compensation
Ticker: VXRT · Form: 8-K · Filed: Mar 6, 2024 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Mar 6, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $600,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-appointment, officer-compensation
Related Tickers: VXRT
TL;DR
Vaxart shakes up leadership with a new CMO and board member, plus compensation details.
AI Summary
Vaxart, Inc. announced on March 4, 2024, the appointment of Dr. Sean Tucker as Chief Medical Officer and the election of Dr. Amy Peterson to its Board of Directors. The company also disclosed compensatory arrangements for its officers. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
Changes in key leadership roles and disclosure of executive compensation can signal shifts in company strategy and provide insights into management's confidence and financial planning.
Risk Assessment
Risk Level: medium — Changes in executive leadership and board composition can introduce uncertainty regarding future strategy and operational execution.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- Dr. Sean Tucker (person) — Appointed Chief Medical Officer
- Dr. Amy Peterson (person) — Elected to Board of Directors
- March 4, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Vaxart, Inc.?
Dr. Sean Tucker has been appointed as the new Chief Medical Officer of Vaxart, Inc.
Who has been elected to the Board of Directors of Vaxart, Inc.?
Dr. Amy Peterson has been elected to the Board of Directors of Vaxart, Inc.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is March 4, 2024.
What type of filing is this with the SEC?
This is a Current Report (Form 8-K) pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What information regarding officers is disclosed in this filing?
The filing discloses the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.
Filing Stats: 1,237 words · 5 min read · ~4 pages · Grade level 10 · Accepted 2024-03-06 09:23:54
Key Financial Figures
- $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M
- $600,000 — which he will receive a base salary of $600,000 per year and will be eligible to partic
Filing Documents
- vxrt20240305c_8k.htm (8-K) — 33KB
- ex_635311.htm (EX-10.1) — 26KB
- ex_635326.htm (EX-99.1) — 14KB
- 0001437749-24-006743.txt ( ) — 217KB
- vxrt-20240304.xsd (EX-101.SCH) — 3KB
- vxrt-20240304_def.xml (EX-101.DEF) — 11KB
- vxrt-20240304_lab.xml (EX-101.LAB) — 15KB
- vxrt-20240304_pre.xml (EX-101.PRE) — 11KB
- vxrt20240305c_8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 4, 2024, the Board of Directors (the "Board") of Vaxart, Inc. (the "Company") appointed Steven Lo as the Company's Chief Executive Officer, President, and principal executive officer, as well as a member of the Board, in each case effective as of March 18, 2024 (the "Start Date"). In connection with Mr. Lo's appointment, Michael J. Finney, Ph.D. will step down as the Company's Interim President and Chief Executive Officer and principal executive officer on the Start Date; however, Dr. Finney will continue to serve as Chair of the Board. Mr. Lo, age 56, has over 25 years of experience in healthcare, biotechnology, and pharmaceutical industries, including over 12 years of C-level experience in publicly traded biotech companies. Prior to joining the Company, Mr. Lo served as Chief Executive Officer and a member of the board of directors of Valitor, Inc., a private biotech company, from August 2022 to March 2024. From October 2019 to August 2022, Mr. Lo was the President, Chief Executive Officer, and member of the board of directors of Zosano Pharma Corporation, a clinical-stage biopharmaceutical company. From September 2015 to October 2019, he was the Chief Commercial Officer at Puma Biotechnology, Inc., a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. At that company, he built and led business development and the worldwide commercialization of the company's first product. Prior to that, he was Chief Commercial Officer of Corcept Therapeutics Incorporated, where he established the commercial organization to launch the company's first product. Earlier in his career, he spent 13 years at Genentech, Inc., a member of Roche Group, in a variety of leadership roles of increasing responsibility in commercial and drug development.
01
Item 8.01 Other Events. On March 6, 2024, the Company issued a press release announcing the appointment of Mr. Lo as the Company's Chief Executive Officer, President, principal executive officer, and a member of the Board. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and, other than the quotes by Dr. Finney and Mr. Lo, is incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 10.1 Letter Agreement, between Vaxart, Inc. and Steven Lo. 99.1 Press Release, dated March 6, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VAXART, INC. Dated: March 6, 2024 By: /s/ Michael J. Finney Michael J. Finney, Ph.D. Interim Chief Executive Officer